Several lines of research indicate that osteoarthritis (OA) is not only a joint disorder associated with mechanical stress and aging but also a 'metabolic syndrome' in which several risk factors work together to contribute to disease initiation and/or development. One such metabolic risk factor could be high cholesterol levels in the body. Even though high cholesterol level is a well-known risk factor for cardiovascular disorders, its possible role in musculoskeletal diseases, particularly OA, is not clear. The authors discuss the fundamental viewpoints on cholesterol involvement in the pathogenesis of OA, stressing the need for understanding the molecular mechanisms behind this association. This is the area of research needed to provide knowledge on how one should live to prevent OA development as well as to suggest new targets for drug therapy.
INTRODUCTION
High fat intakes and inactive lifestyles are main health issues in today's modern world. They have resulted in an increasing prevalence of high blood pressure, obesity, dyslipidemia, hypercholesterolemia, and a condition identified as 'insulin-resistance syndrome or metabolic syndrome'. Metabolic syndrome is well recognized as a risk factor for diabetes, cardiovascular disease and atherosclerosis. Recently, it has been reported that most of these conditions may also be associated with an increased risk of osteoarthritis (OA). [1] [2] [3] To complicate matters further, these risk factors can reportedly interact with each other, worsening the disease rate and state. However, the majority of OA is induced by metabolic risk factors such as obesity, high blood pressure, hypercholesterolemia; and diabetes can be treated, controlled, and/or modified. Therefore, understanding the mechanisms by which these systemic factors change the development of OA should be an intense area of research to direct patient targeted therapies.
CHOLESTEROL: A NEW RISK FACTOR FOR INITIATING OA
The cellular cholesterol biosynthetic pathway and dietary intake are the sources of the body's total cholesterol. Most cell types, including the chondrocytes, are able to synthesize cholesterol through the biosynthesis pathway. Cholesterol, a vital cellular membrane component, in conjunction with other intermediates of the cholesterol biosynthetic pathway, controls signaling molecules such as Ras, Hedgehog and Rho. It has been reported that the human synovial fluid contains low concentrations of cholesterol compared to plasma levels,; however, the synovial fluid of patients with inflammatory joint conditions has been well-known to contain higher amounts of cholesterol and cholesterol crystals compared with synovial fluid of normal individuals. [4] [5] [6] The mechanisms responsible to account for this increase in the cholesterol amount in synovial fluid
have not yet been established. However, it is possible that the synovial cells may have the capacity to synthesize some of the lipids found in synovial fluid.
People who are overweight or obese tend to develop hypercholesterolemia due to changes in fat metabolism. However, there is a debate as to whether high cholesterol levels affect the incidence of OA. Epidemiologic studies drew diverse conclusions on the subject of the link between OA and high serum cholesterol levels. Several reported a positive link between hypercholesterolemia and OA, [9] [10] [11] [12] [13] whereas others found a negative correlation.
14 A summary of the epidemiologic studies on the subject of a link between OA and high serum cholesterol levels are reported in Table 1 .
Abnormal cholesterol accumulation occurs when cholesterol influx into the tissue wall (from apolipoprotein B [APOB]-containing lipoproteins) goes beyond cholesterol efflux. In a more recent study, it has been reported that messenger RNA (mRNA) expression levels of cholesterol transport genes such as APOA-1 and adenosine triphosphate (ATP)-binding cassette transporter 1 (ABCA1) were significantly reduced in OA cartilage compared to the normal. Furthermore, mRNA expression levels of the two subtypes of liver X receptor (LXR), specifically LXRa and LXRb, were also significantly reduced in OA cartilage. 16 Interestingly, the same group also showed a central role of up-regulated sterol regulatory element-binding proteins (SREBP-2) in the pathogenesis of OA as well as potential involving mechanisms. 17 This is further supported by proteomic analysis data showing that several lipid metabolismrelated proteins are diversely expressed in OA cartilage compared to the normal. 18, 19 The differential expression pattern of these cholesterol regulatory genes between normal and OA cartilage may signify a causal relationship of cholesterol-related mechanisms to OA development.
Recently, Gierman and co-workers found an association between metabolic stimuli and spontaneous OA development in mice. They showed that a high-fat diet can induce cartilage degradation independent of body weight, and decreasing cholesterol levels may eliminate this effect. 20 In a later study, this group also indicated that dietary cholesterol contributes to OA development in an APOE*3Leiden (ApoE À/À ) mice model providing the first direct evidence for cholesterol involvement in OA. 21 In their study they have demonstrated that increased dietary cholesterol can cause OA development In this study of asymptomatic middle-aged women with no clinical knee OA, high serum cholesterol and triglyceride levels were associated with the incidence of bone marrow lesions over 2 years in a mouse model. They further showed that such an OA development can be inhibited by atorvastatin, a member of the drug class known as statins. To better study the particular role of cholesterol in OA development, they used the drug ezetimibe, which decreases intestinal cholesterol absorption and consequently, decreases serum cholesterol levels in animals fed with cholesterol-rich diet. In that study, ezetimibe therapy did not correct OA development significantly when subjects were fed a cholesterol-rich diet, suggesting that the processes independent of cholesterol exposure may also contribute to OA development. In both studies, the authors proposed that inflammation is responsible for causing cholesterol-induced cartilage degradation rather than excess mechanical load. One of the features of hypercholesterolemia is increased levels of low-density lipoproteins (LDL). LDL is a heterogeneous class of lipoprotein particles consisting of a hydrophobic core containing triglycerides and cholesterol esters in a hydrophilic shell of phospholipids, free cholesterol, and APOs, predominantly B-100. In a more recent study, de Munter et al. studied the effect of high systemic LDL cholesterol levels independent of weight in ApoE À/À mice. They found that the increased synovial inflammation and accelerated ectopic bone formation during experimental OA are derived from high LDL levels. 22 Koskinen and colleauges found that elevated levels of LDL (by LDL-receptor deficiency or a cholesterol-rich diet), in an inflammatory OA model, induced pathology. In mice with high LDL levels, synovial production of pro-inflammatory cytokines were increased, signifying synovial activation in response to high LDL levels. 23 Apart from a rodent animal model, the association of chondrocyte lipid peroxidation to cartilage matrix degradation in OA were also reported in the rabbit animal model of the disease by Tiku et al. 24 Our own studies by using ApoE À/À mice and diet-induced hypercholesterolemia (DIHC) rats, we explored the effects of hypercholesterolemia on the progression of OA. Both models exhibited OA-like changes, characterized by cartilage degradation, osteophyte formation, changes to subchondral bone architecture. Surgical destabilization of the knees resulted in a dramatic increase of degradative OA symptoms in animals fed a high-cholesterol diet compared with controls. 25 These results together emphasize the importance of cholesterol in the pathogenesis of OA. Despite the fact that the above studies have demonstrated important and complex interactions between cholesterol and OA, the mechanisms behind this correlation remain unclear. To better understand this association, further investigations are required to address underlying molecular mechanism.
HOW COULD CHOLESTEROL DAMAGE THE CARTILAGE?
The mechanisms underlies this association are yet unanswered, but there are a number of ways that cholesterol can cause cartilage damage and these hypotheses are reviewed here.
OA and atherosclerosis: Do they have a common molecular mechanism?
Current information suggests that OA development can be partially associated with the alterations of blood vessel function, which is associated with atherosclerosis. [26] [27] [28] Since cholesterol is a main component of the cell membrane, any alterations could affect function and fluidity of the membrane so that poor cell behavior and cholesterol accumulation results. 29 It is possible that hypercholesterolemia induces the oxidation and deposition of lipids in tissues, causing damage to cartilage similar to what we see in diseases like atherosclerosis. 30 A key contributing factor for atherosclerotic lesion incidence most likely is the imbalance between cholesterol influx and efflux regulation within the tissue. 31 The influx and efflux of cholesterol is well-known to be regulated by several cell surface receptors, including CD36, ABCA1 and scavenger receptor class B type I (SR-BI). 32 The first step in reverse cholesterol transport is related to ABCA1, a transmembrane protein mediating lipid efflux from cells to APO. It has been established that ABCA1 plays an essential role in cholesterol homeostasis, and alterations in this gene were associated with atherosclerosis. 33, 34 SR-BI is a member of the CD36 superfamily, which is mostly expressed in the steroidogenic tissues and liver, where it facilitates selective cholesteryl ester uptake from high-density lipoprotein (HDL). 35, 36 Furthermore, SR-BI is expressed in macrophages such as those in atherosclerotic lesions, monocyte-derived macrophages and tissue macrophages. 37, 38 SRBI deficiency is related to de-regulation of cholesterol homeostasis in the arterial wall, which leads to greater susceptibility to atherosclerosis. 39 CD36 has been recognized as a binding and internalizing factor for oxidized LDL (oxLDL) and a wide range of ligands such as long-chain fatty acids, apoptotic cells, anionic phospholipids and other altered LDL.
40 CD36 plays a role as a governing scavenger receptor in the oxLDL uptake and recognizes lipid moieties of oxLDL. 41 Moreover, increasing evidence proposes that peroxisome proliferator activated receptors (PPARs) 42, 43 utilize antiatherogenic effects through increasing cholesterol efflux by stimulation of the liver X receptor (LXR)-ABCA1 pathway. [44] [45] [46] [47] It is possible that the same genes and molecular determinants in atherosclerosis could affect cartilage cholesterol homeostasis. This hypothesis is more supported by the study showing the expression of some of those genes in the cartilage tissue. 16 In this context, earlier reports suggest that cholesterol is essential for bone formation and chondrocyte differentiation. 7 The expression of proteins involved in cholesterol metabolism is strongly regulated in chondrocytes. For example, the expressions of APOA-1 and ABCA1 were high in differentiating chondrocytes, and reduce to basal level once cells become hypertrophic. In contrast, hypertrophic chondrocytes express the highest level of serum amyloid A (SAA) mRNA. 7, 8 The results from these studies propose that the use and synthesis of cholesterol have to be strongly regulated to avoid abnormal deposition of cholesterol in joint tissues and hyperlipidemia, similar to vessels. Supporting this notion, a study has shown that synovial fluid of OA patients showed dysregulated lipid profile and correlated with inflammatory parameters in the OA joint cavity. The same authors demonstrated that APOA-1 expression as well as HDL and LDL concentrations would influence the inflammatory properties of cholesterol regulating gene APOA-1 in chondrocytes and fibroblast-like synoviocytes. 48 Another study has demonstrated that sterol regulatory element binding proteins (SREBPs), a key transcription factor regulating cholesterol metabolism, is involved in OA pathogenesis. 17 In a recent study, importance of hedgehog signaling in chondrocytes has been demonstrated in regulating cholesterol homeostasis. Hedgehog signaling regulates cholesterol homeostasis in chondrocytes, and alterations lead to intracellular cholesterol accumulation contributing to the severity of OA. 49 Also, a study showed that miR-33a regulates cholesterol synthesis through the transforming growth factor (TGF)-b1/Akt/ SREBP-2 pathway, as well as cholesterol efflux-related genes ABCA1 and APOA-1, in OA chondrocytes. 50 In another view, Findlay et al. proposed that blood vessel alterations may cause changed blood flow to the subchondral bone. Consequently, the cartilage and the bone are deprived of oxygen, nutrients and blood that leads to complete tissue degeneration. 51 Since cholesterol is known to be a predominant factor that influences altered blood vessel function, it is possible that the above chains of events can lead to OA.
Is inflammation playing a role in the association between high cholesterol levels and OA?
Obesity and associated metabolic syndromes are related to systemic tissue damage and chronic low-grade inflammation. 52 Continuous lipoprotein accumulation, mainly LDL, in the extracellular matrix of cartilage can trigger the inflammatory process. C-reactive protein (CRP) is a very sensitive inflammatory marker. In OA, enhanced levels of CRP and interleukin (IL)-6 have been found, a finding indicative of the incidence of inflammation. In this respect, the fact that CRP is associated with obesity is noteworthy. A positive association between circulating CRP has been demonstrated in patients with obesity, metabolic syndrome and OA. 53 IL-6 is a proinflammatory cytokine which is produced by many cells including chondrocytes. Expression studies have also shown increased levels of IL-6 mRNA in OA specimens. Elevated high-sensitivity CRP levels are associated with local inflammatory findings in patients with OA. 54 Remarkably, IL-6 seems to be related to visceral obesity and insulin resistance. 55 Recent studies clearly highlight the close link between inflammation and cholesterol homeostasis through mechanisms in which ABCA1 appears to be a major actor. For example, increased intracellular free cholesterol concentration in ABCA1 knockout (KO) macrophages is accompanied by enhanced inflammatory response in macrophages. 56 Transcription factor nuclear factor-jB (NF-jB) is another molecule which plays a vital role in lipidinduced inflammation. Its essential role is regulating inflammation and immune responses by activation of different genes, including those that encode adhesion molecules, growth factors and cytokines. NF-jB is a redox sensitive molecule and triggered by radicals. A large number of different radicals may be derived from oxidation of lipoproteins, activating the pro-inflammatory NF-jB, which can induce inflammation in the vascular wall. Interestingly, it has been reported that the induction of hypercholesterolemia in pigs, rabbits, mice and many other animals leads to vascular inflammation within 6-8 weeks.
57-59
Can high cholesterol levels trigger mitochondrial function and oxidative stress?
Mitochondria are small membrane-enclosed beanshape organelles, which exist in all eukaryotic cells. 60 Mitochondria are very important organelles that contribute to cellular homeostasis, differentiation, metabolism and survival. They do not simply contribute to energy production, but also to other cellular activities such as apoptosis induction, signal cascade and calcium buffering. 61 Mitochondrial dysfunction is known to be induced by hyperglycemia, hypertriglyceridemia, hypercholesterolemia and even the course of aging. 62, 63 It has been found that in some pathological states, mitochondria are enriched with high levels of cholesterol. [64] [65] [66] Regardless of the physiological role of cholesterol in mitochondria, the underlying mechanisms for transferring to this organelle are not fully documented. It has been found that the relative amount of fatty acid chains and the interactions between cholesterol and phospholipids, as important constituents of biological membranes, may influence physical resistance and permeability of membranes including mitochondrial membranes. 67 Recent observations have reported the activity of cholesterol-transporting polypeptides, including the steroidogenic acute regulatory protein (StAR) that contributes to the mitochondrial intermembrane trafficking of cholesterol. 68, 69 There is increasing evidence documented that cholesterol enrichment in mitochondria can impair specific mitochondrial components accounting, in part, for the mitochondrial dysfunction described in cells. [70] [71] [72] The mechanisms by which free cholesterol overloading activates these events may be conducted by activation of death-promoting molecules or by direct membrane effects or both. 73, 74 Numerous studies have shown an association of increased cholesterol oxidation products (oxysterols) to mitochondrion-derived oxidative stress, which typically causes overproduction of mitochondrial reactive oxygen species (mtROS). 75 Excessive and continuous accumulation of oxidized cholesterol particles tends to bind to sulfate-containing proteoglycans, where they aggregate and get oxidatively modified. The elements that are in charge of these modifications remain to be identified, but apart from ROS, a variety of membrane and extracellular tissue-related enzymes have been reported to be involved. 76 Different defense mechanisms, such as enzymes and antioxidant vitamins, serve to inhibit oxidative damage derived from lipoproteins accumulation, but under constant lipid overload situation these defense mechanisms may finally not function, causing the activation of stress signaling pathways. 77 ROS is typically produced by mitochondria and, in optimal situations, are neutralized by the mitochondrial cellular defense mechanisms. Overproduction of ROS can impair mitochondrial oxidative stress defenses, cause irreversible harm at the cellular and molecular levels in vulnerable cells, and contribute to pathologic conditions via activation of oxidative stress-induced pathways 78 ( Fig. 1) . ROS can also damage cellular lipids, proteins and DNA, prompting lipid peroxidation, a condition that can stimulate more mtDNA damage. 79 These observations suggest a mechanistic explanation that loading free cholesterol prompts high levels of superoxide anions, enhances oxidative stress and activates a transitory inflammatory reaction causing permanent damage to the tissue. Elevated ROS production, especially radicals resulting from superoxide, has been related to cartilage dysfunction in human 80 and animal models 81 of disease, and there is growing evidence of a link between oxidative stress and cartilage degeneration in humans. 82, 83 However, whether high cholesterol levels trigger mitochondrial dysfunction in cartilage needs further investigation to suggest antioxidant therapy for this specific risk group. In our recent study, we showed that excessive cholesterol levels can affect chondrocyte mitochondrial function.
We showed that cholesterol-stimulated chondrocytes assessed by transmission electron microscopy (TEM) showed mitochondria with irregular morphologies.
We further observed decreased rhodamine123 fluorescence intensities upon cholesterol treatment, representing mitochondrial membrane depolarization indicating mitochondrial dysfunction. Furthermore, cellular ATP content was decreased in cholesterol-stimulated chondrocytes compared to controls. We also found that cellular ROS levels were increased in chondrocytes treated with high cholesterol. These results together indicate that elevated cholesterol induces mitochondrial dysfunction and increases ROS in chondrocytes. By addressing the mitochondrial dysfunction using mitochondria-targeted antioxidants, we were able attenuate the OA progression in ApoE À/À mice and DIHC rats. 87 Furthermore, it has been demonstrated that mevastatin enhances the mRNA levels of bone morphogenetic protein-2, collagen type II and aggrecan along with elevating proteoglycan synthesis in rat chondrocytes, 88 while Yudoh and his colleagues' findings propose that statin may be capable of inhibiting the catabolic stress-induced chondrocyte disability and aging detected in articular cartilage of STR/OrtCrlj mice which spontaneously develop OA. 89 By virtue of the various immunomodulatory and chondro-protective functions exerted by statins, they may be able to reduce the damage. However, there are a few questions still remaining, and the most important uncertainty is to what extent cholesterol should be reduced to nullify any off-target effects and to maintain the levels required for cartilage homeostasis.
With currently available agents it is feasible to achieve any required levels of cholesterol in most people. We also are aware that no miracle drug can be used for all OA patients' treatments. Therefore, classifying OA patients into variable phenotypes according to their risk factors would expedite the development of drugs functioning directly toward variable courses of OA. However, such an individualization of disease treatment will possibly less attract the pharmaceutical industry seeking epic medications that fit everyone, but in our opinion this should be the strategy to target OA. A more immediate impact from understanding the role of cholesterol in OA may be evident in the role of orthopedic surgeons in a patient's overall health care. If a well-established association is found between high cholesterol and OA, an orthopedist might recommend a lipid test when he or she sees a patient, especially if there is no apparent extrinsic cause. Furthermore, if high cholesterol levels were detected in the blood there is an opportunity to make lifestyle changes to reach a safe cholesterol level.
CONCLUSION
The opinion that cholesterol as a risk factor for OA has developed lately; however, the molecular Fig. 1 Schematic representation of cholesterol effects on chondrocytes. ABCA, ATP-binding cassette transporter; APO, apolipoprotein; ATP, adenosine triphosphate; IKKb, inhibitor of nuclear factor kappa-b; JNK, c-jun-NH,-kinase; IL, interleukin; LDL, low-density lipoprotein; LXR, liver X receptor; RXR, retinoid X receptor; mtDNA, mitochondrial DNA; PKC, protein kinase C; ROS, reactive oxygen species; RXR,; TNF, tumor necrosis factor. mechanism underlying this association is not clear. It is important to understand how metabolic risk factors such as high cholesterol levels contribute to the development of OA because most of the risk factors can be modified with simple life style changes without the need of surgical interventions or expensive drug and medical treatments. We believe reduction in levels of cholesterol by drug or food intake and lifestyle constitutes one of the cornerstones in the prevention of OA onset and progression in a specific risk group, but further investigation in this area is needed to advise the public how to live to decrease the risk of OA as well as suggest new targets for drug therapy.
